

## Dasatinib Dr.Reddy's

Active ingredient: dasatinib

---

### Consumer Medicine Information

This leaflet provides important information about Dasatinib Dr.Reddy's. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Dasatinib Dr.Reddy's.

*Where to find information in this leaflet:*

1. **Why am I using Dasatinib Dr.Reddy's?**
2. **What should I know before I use Dasatinib Dr.Reddy's?**
3. **What if I am taking other medicines?**
4. **How do I use Dasatinib Dr.Reddy's?**
5. **What should I know while using Dasatinib Dr.Reddy's?**
6. **Are there any side effects?**
7. **Product details**

---

#### 1. Why am I using Dasatinib Dr.Reddy's?

---

Dasatinib Dr.Reddy's is used to treat adults and children with chronic myeloid leukaemia (CML). It is also used to treat adults and children who have a particular form of acute lymphoblastic leukaemia (ALL) called Philadelphia chromosome positive or Ph+ ALL. Leukaemia is a cancer of immature white blood cells, which grow in the bone marrow.

Under normal circumstances, as these white blood cells mature, they enter the blood stream where they fight infection and maintain the body's immune system. In leukaemia, these immature white blood cells multiply in an uncontrolled manner, occupying the bone marrow space and spilling out into the bloodstream.

As a consequence, the production of normal red blood cells (oxygen carrying cells), white blood cells (cells which fight infection), and platelets (cells which help blood to clot) is compromised. Therefore patients with leukaemia are at risk of developing serious anaemia, infections and bleeding.

It is intended that Dasatinib Dr.Reddy's be used in adults with:

- newly diagnosed Ph+ CML in the chronic phase.
- chronic, accelerated or myeloid or lymphoid blast phase CML with resistance to prior therapy.
- newly diagnosed Ph+ acute lymphoblastic leukaemia integrated with chemotherapy.
- Ph+ acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.